GB:PRTC Stock Latest News
Company AnnouncementsPureTech’s Gallop Oncology Readies LYT-200 for Phase 2 After Positive Early Data1w ago
Company AnnouncementsPureTech-Founded Seaport Therapeutics Unveils Strong Phase 1 Data for GlyphAgo3w ago
Company AnnouncementsPureTech-Founded Seaport Therapeutics Doses First Patient in Mid-Stage GAD Trial of GlyphAgo3w ago
Company AnnouncementsPureTech Health Charts Leaner Path After Strong Pipeline Progress1M ago
Company AnnouncementsPureTech pivots to leaner, capital-light model as portfolio advances and Seaport IPO boosts asset base1M ago
Company AnnouncementsPureTech’s Gallop Oncology Wins FDA Fast Track for LYT-200 in High-Risk MDS1M ago- Company AnnouncementsPureTech updates share capital and voting rights as of August 20262M ago
Company AnnouncementsPureTech’s Celea to Spotlight Phase 3 IPF Drug Deupirfenidone at ERS Congress2M ago
Company AnnouncementsPureTech Health Issues RSU-Based Shares to Senior Management2M ago
Company AnnouncementsPureTech updates share capital and voting rights as it emphasizes R&D-driven growth3M ago
Company AnnouncementsPureTech Health Awards Vested RSUs to Non-Executive Directors, Updates Share Capital3M ago
Company AnnouncementsPureTech Insiders Boost Holdings with Coordinated Share Purchases3M ago- Company AnnouncementsPureTech Spins Out Celea with $180 Million to Advance Phase 3 IPF Drug4M ago
- Company AnnouncementsPureTech Spins Out Celea in $180m IPF Bet, Sharpening Lean Portfolio Strategy4M ago
Company AnnouncementsPureTech Health Wins Full Shareholder Backing at 2026 AGM4M ago
Company AnnouncementsPureTech’s Seaport Unit Advances GlyphAgo After Positive Phase 1 Anxiety Drug Data4M agoCompany AnnouncementsPureTech Showcases Phase 3 Deupirfenidone Push to Raise IPF Treatment Bar5M ago
Company AnnouncementsPureTech’s Founded Entity Seaport Therapeutics Prices Upsized $254.9 Million Nasdaq IPO6M ago
